Express develops tumor microenvironment to activate innovative immunotherapy, cutting-edge exploration of new strategies for solid tumor treatment

▎Editor of WuXi AppTec's content team On January 3, 2022, Amberstone Biosciences announced the completion of a US$12 million Series A financing
.

The funds obtained from the financing will be used to advance its highly differentiated tumor microenvironment activation therapy (T-MATE) research and development project to support the IND application research stage, which includes bispecific antibodies and immune cytokines activated by the tumor microenvironment
.

 Amberstone's T-MATE therapeutic molecules are developed through AmberFlow, its drug discovery platform based on microfluidics technology
.

This platform can analyze the function of single cells in an adjustable microenvironment and efficiently isolate rare high-quality antibody drug candidates
.

Image source: Amberstone Biosciences official website Amberstone President and CEO Dr.
George Wu said: "Through our unique T-MATE project, Amberstone aims to develop safer and more effective innovative therapies that benefit cancer patients
.

Our investors The funding provided and the extensive expertise and resources in this field will bring us one step closer to this goal
.

" Dr.
Xin Huang, one of the lead investors in this round of financing and the managing partner of Co-win Ventures, said: "T Cellular immunotherapy has encountered huge challenges in the complex microenvironment of solid tumors
.

The T-MATE molecule discovered through Amberstone's interdisciplinary drug discovery engine will break through the bottleneck of traditional methods and bring new hope for solid tumor treatment
.

We are very happy to work with Amberstone to explore next-generation immunotherapy for solid tumors
.

"Reference: [1] Amberstone Biosciences Secures $12 Million Series A Financing to Advance Immuno-Oncology Pipeline of Tumor Microenvironment Activated Therapeutics.
Retrieved January 3, 2021, from https:// en/Amberstone-Biosciences-Secures-12-Million-Series-A-Financing-to-Advance-Immuno-Oncology-Pipeline-of-Tumor-Microenvironment-Activated-Therapeutics Disclaimer: WuXi AppTec's content team focuses on introducing global biomedicine Health research progress
.

This article is for the purpose of information exchange only.
The views in the article do not represent WuXi AppTec’s position, nor does it mean that WuXi AppTec supports or opposes the views
in the
article .
This article is not a treatment plan recommendation
.

If you need treatment plan guidance, please go to the official website.
Visit the hospital
.